NEW YORK (GenomeWeb News) – The Sanford-Burnham Medical Research Institute said today that its investigators will collaborate with Pfizer to identify therapeutic targets for use in preventing and treating complications related to obesity and diabetes.

Under the three-year collaboration, the partners at Pfizer and Sanford-Burnham's Conrad Prebys Center for Chemical Genomics will use novel screening tools and systems biology approaches to develop treatment methods for reducing insulin resistance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.